Answers are grounded in this paper and cite their sources.
The review summarizes current approaches to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative early breast cancer. It discusses clinicopathological and biological recurrence-risk factors, assessment of endocrine sensitivity, and criteria for treatment intensification. Evidence on extended endocrine therapy, ovarian suppression, aromatase inhibitors, and the addition of CDK4/6 inhibitors is presented. Particular attention is paid to prevention of bone loss, management of adverse events, drug-drug interactions, lifestyle modification, and treatment adherence. Individual treatment selection should account for the expected absolute benefit, toxicity, comorbidities, menopausal status, and patient preferences. Adjuvant endocrine therapy is viewed as a dynamic clinical management process that requires regular assessment of efficacy and safety, prevention of complications, and timely treatment modification.
No takes yet. Share an insight, caveat, or question.
Артамонова et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: